BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alvarado-Ortiz E, de la Cruz-López KG, Becerril-Rico J, Sarabia-Sánchez MA, Ortiz-Sánchez E, García-Carrancá A. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. Front Cell Dev Biol 2020;8:607670. [PMID: 33644030 DOI: 10.3389/fcell.2020.607670] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Nikitaki Z, Velalopoulou A, Zanni V, Tremi I, Havaki S, Kokkoris M, Gorgoulis VG, Koumenis C, Georgakilas AG. Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair. Expert Rev Mol Med 2022;24:e15. [PMID: 35357290 DOI: 10.1017/erm.2022.6] [Reference Citation Analysis]
2 Meneghetti BV, Wilson R, Dias CK, Cadore NA, Klamt F, Zaha A, Ferreira HB, Monteiro KM. p53 mutants G245S and R337H associated with the Li-Fraumeni syndrome regulate distinct metabolic pathways. Biochimie 2022. [DOI: 10.1016/j.biochi.2022.03.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rahman MA, Park MN, Rahman MH, Rashid MM, Islam R, Uddin MJ, Hannan MA, Kim B. p53 Modulation of Autophagy Signaling in Cancer Therapies: Perspectives Mechanism and Therapeutic Targets. Front Cell Dev Biol 2022;10:761080. [DOI: 10.3389/fcell.2022.761080] [Reference Citation Analysis]
4 Hsin IL, Shen HP, Chang HY, Ko JL, Wang PH. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines. Cells 2021;10:2916. [PMID: 34831139 DOI: 10.3390/cells10112916] [Reference Citation Analysis]
5 Pantziarka P, Blagden S. Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome. Cancers (Basel) 2022;14:1621. [PMID: 35406393 DOI: 10.3390/cancers14071621] [Reference Citation Analysis]
6 Zavileyskiy L, Bunik V. Regulation of p53 Function by Formation of Non-Nuclear Heterologous Protein Complexes. Biomolecules 2022;12:327. [PMID: 35204825 DOI: 10.3390/biom12020327] [Reference Citation Analysis]
7 Sadahiro Y, Hitora Y, Tsukamoto S. Colletofragarone A2 and Colletoins A-C from a Fungus Colletotrichum sp. Decrease Mutant p53 Levels in Cells. J Nat Prod 2021;84:3131-7. [PMID: 34854682 DOI: 10.1021/acs.jnatprod.1c00913] [Reference Citation Analysis]
8 Loughran RM, Emerling BM. Mechanistic roles of mutant p53 governing lipid metabolism. Adv Biol Regul 2021;:100839. [PMID: 34840111 DOI: 10.1016/j.jbior.2021.100839] [Reference Citation Analysis]
9 Siolas D, Vucic E, Kurz E, Hajdu C, Bar-Sagi D. Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell Rep 2021;36:109578. [PMID: 34433022 DOI: 10.1016/j.celrep.2021.109578] [Reference Citation Analysis]
10 Razlog R, Kruger CA, Abrahamse H. Enhancement of Conventional and Photodynamic Therapy for Treatment of Cervical Cancer with Cannabidiol. Integr Cancer Ther 2022;21:15347354221092706. [PMID: 35481367 DOI: 10.1177/15347354221092706] [Reference Citation Analysis]
11 Kuo KK, Hsiao PJ, Chang WT, Chuang SC, Yang YH, Wuputra K, Ku CC, Pan JB, Li CP, Kato K, Liu CJ, Wu DC, Yokoyama KK. Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer. Cancers (Basel) 2021;13:3920. [PMID: 34359820 DOI: 10.3390/cancers13153920] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Mammarella E, Zampieri C, Panatta E, Melino G, Amelio I. NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network. Biol Direct 2021;16:11. [PMID: 34348766 DOI: 10.1186/s13062-021-00296-5] [Reference Citation Analysis]
13 Kong X, Yu D, Wang Z, Li S. Relationship between p53 status and the bioeffect of ionizing radiation. Oncol Lett 2021;22:661. [PMID: 34386083 DOI: 10.3892/ol.2021.12922] [Reference Citation Analysis]
14 Patra T, Meyer K, Ray RB, Kanda T, Ray R. Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells. Cell Death Dis 2021;12:1073. [PMID: 34759291 DOI: 10.1038/s41419-021-04371-7] [Reference Citation Analysis]
15 You KS, Yi YW, Cho J, Park JS, Seong YS. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals (Basel) 2021;14:589. [PMID: 34207383 DOI: 10.3390/ph14060589] [Reference Citation Analysis]